AbbVie to Unveil Promising Phase 3 Etentamig Data at 2026 International Myeloma Society Annual Meeting
AbbVie, a global leader in biopharmaceuticals, is poised to share significant findings from its expansive multiple myeloma research portfolio at the 2026 International Myeloma Society (IMS) Annual Meeting, which will be held from September 23-26 in Glasgow, Scotland. The highlight of AbbVie's presentation will be the Phase 3 results from the CERVINO trial, investigating the investigational drug etentamig, a second-generation bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3.
The CERVINO trial aimed to evaluate the efficacy of etentamig in patients with relapsed or refractory multiple myeloma (RRMM) who have been exposed to multiple prior therapies. The topline data from the study revealed statistically significant improvements in the study's primary endpoints: objective response rate (ORR) and progression-free survival (PFS). These results underscore the potential of etentamig to offer beneficial outcomes for patients facing this complex and often challenging disease.
In addition to the CERVINO study, AbbVie will present diverse data that showcases the breadth of its myeloma pipeline. This includes investigational agents like ABBV-2001, a trispecific T-cell engager targeting CD38, BCMA, and CD3, and surzetoclax, a small-molecule BCL-2 inhibitor. These presentations will discuss various treatment strategies, including treatment sequencing, healthcare resource utilization, and real-world outcomes that enhance the understanding of multiple myeloma heterogeneity.
Daejin Abidoye, M.D., Vice President and Therapeutic Area Head at AbbVie, stated, "Despite the progress made in treating multiple myeloma, the disease remains incurable, and we need to address the issues of treatment resistance, disease heterogeneity, and patient tolerance. Our participation at IMS is indicative of our commitment to developing our differentiated myeloma portfolio with targeted therapies and combination approaches that align with the complexities of this disease. Our goal is to provide more precise, durable, and better access to treatment options for patients."
AbbVie’s presentations at the IMS will include a variety of topics, reflecting its ongoing commitment to advancing knowledge and strategies in multiple myeloma treatment. Notable sessions will cover:
1. Insights on real-world characteristics and treatment patterns in Europe using the HARMONY Big Data Platform.
2. Evaluating the safety and efficacy of etentamig both alone and in combination with other therapies in patient populations.
3. A focus on infection-related healthcare resource utilization and associated costs in patients receiving T-cell redirecting therapies.
By advancing its scientifically differentiated portfolio, AbbVie aspires to enhance patient outcomes in the face of multiple myeloma’s evolving landscape. The data presented at the IMS will surely contribute to dialogues on how to effectively tackle patient needs, resistance mechanisms, and overall treatment efficacy.
All presentations will be scheduled according to local Glasgow time, and specific timings for key abstract presentations have been released in anticipation of the meeting. This expansive range of studies reinforces AbbVie's robust approach to addressing multiple myeloma through innovative therapies that pave the way for improved standards of care. Additional details about AbbVie’s participation in the IMS can be accessed through their official communications. Overall, this meeting signifies not just a gathering of the greatest minds in myeloma research but also a pivotal moment for advancements that may reshape patient treatment trajectories.
The CERVINO trial aimed to evaluate the efficacy of etentamig in patients with relapsed or refractory multiple myeloma (RRMM) who have been exposed to multiple prior therapies. The topline data from the study revealed statistically significant improvements in the study's primary endpoints: objective response rate (ORR) and progression-free survival (PFS). These results underscore the potential of etentamig to offer beneficial outcomes for patients facing this complex and often challenging disease.
In addition to the CERVINO study, AbbVie will present diverse data that showcases the breadth of its myeloma pipeline. This includes investigational agents like ABBV-2001, a trispecific T-cell engager targeting CD38, BCMA, and CD3, and surzetoclax, a small-molecule BCL-2 inhibitor. These presentations will discuss various treatment strategies, including treatment sequencing, healthcare resource utilization, and real-world outcomes that enhance the understanding of multiple myeloma heterogeneity.
Daejin Abidoye, M.D., Vice President and Therapeutic Area Head at AbbVie, stated, "Despite the progress made in treating multiple myeloma, the disease remains incurable, and we need to address the issues of treatment resistance, disease heterogeneity, and patient tolerance. Our participation at IMS is indicative of our commitment to developing our differentiated myeloma portfolio with targeted therapies and combination approaches that align with the complexities of this disease. Our goal is to provide more precise, durable, and better access to treatment options for patients."
AbbVie’s presentations at the IMS will include a variety of topics, reflecting its ongoing commitment to advancing knowledge and strategies in multiple myeloma treatment. Notable sessions will cover:
1. Insights on real-world characteristics and treatment patterns in Europe using the HARMONY Big Data Platform.
2. Evaluating the safety and efficacy of etentamig both alone and in combination with other therapies in patient populations.
3. A focus on infection-related healthcare resource utilization and associated costs in patients receiving T-cell redirecting therapies.
By advancing its scientifically differentiated portfolio, AbbVie aspires to enhance patient outcomes in the face of multiple myeloma’s evolving landscape. The data presented at the IMS will surely contribute to dialogues on how to effectively tackle patient needs, resistance mechanisms, and overall treatment efficacy.
All presentations will be scheduled according to local Glasgow time, and specific timings for key abstract presentations have been released in anticipation of the meeting. This expansive range of studies reinforces AbbVie's robust approach to addressing multiple myeloma through innovative therapies that pave the way for improved standards of care. Additional details about AbbVie’s participation in the IMS can be accessed through their official communications. Overall, this meeting signifies not just a gathering of the greatest minds in myeloma research but also a pivotal moment for advancements that may reshape patient treatment trajectories.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.